|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1955
|
|
gptkbp:atccode
|
N06 BA04
|
|
gptkbp:brand
|
gptkb:Daytrana
gptkb:Quillivant_XR
gptkb:Concerta
gptkb:Ritalin_LA
Metadate
Ritalin IR
Ritalin SR
|
|
gptkbp:casnumber
|
113-45-1
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C14 H19 NO2
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart problems
hyperthyroidism
|
|
gptkbp:discontinued
|
Ritalin-CR
Ritalin-ER
Ritalin-IR
Ritalin-ODT
Ritalin-OR
Ritalin-SR
Ritalin-XL
|
|
gptkbp:form
|
gptkb:tablet
oral solution
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ritalin
|
|
gptkbp:ingredients
|
gptkb:Sannin
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:legal_status
|
controlled substance
|
|
gptkbp:lifespan
|
2 to 4 hours
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
headache
nausea
decreased appetite
insomnia
|
|
gptkbp:toxicity
|
moderate
|
|
gptkbp:used_for
|
treatment of ADHD
treatment of narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|